Dendritic cells (DCs) are critical regulators of immune responses. This study was to observe the effect of DCs from peripheral blood on the differentiation of Th17 in patients with rheumatoid arthritis (RA). Peripheral blood samples were collected from 30 patients with RA and 20 healthy controls, respectively. Flow cytometry results showed that in contrast to Treg cells, the proportion of Th17 cells in T cells and the Th17/Treg ratio were both increased in patients with RA. The RT-PCR results showed that Foxp3、ROR ct and miR-363 expression in PBMC of patients with RA were reduced, but the ITGAV expression was increased, which was negatively related to miR-363 expression. IL-17, TGF-b and IL-6 levels detected by ELISA were increased in peripheral blood serum of patients with RA. Moreover, we noted that the CD11C + am + /CD11C + DCs ratio was obvious increased in patients with RA and has positive correlation to the Th17/Treg ratio. In cocultured system, Th17 cell differentiation was significantly inhibited in the presence of ITGF-b suggesting that Th17 cell differentiation was controlled by active TGF-b (aTGF-b). After DCs transfecting with miR-363 mimics and cocultured with T cells, Th17 cell number, IL-17 level and ROR-ct expression were significantly reduced in the presence of latent TGF-b (ITGF-b). In addition, the integrin av protein expression was both reduced in the presence of aTGF-b or ITGF-b. These data demonstrated that DCs induced Th17 cell differentiation through miR-363/Integrin av/TGF-b pathway in patients with RA.
Introduction
Dendritic cells (DCs) are antigen-presenting cells originating from bone marrow and localize in lymphoid organs to initiate and regulate primary and secondary immune responses [1] . Nishikawa et al. [2] have reported that the DCs possessed the unique ability to activate naive T lymphocytes during their first contact with antigen. According to most studies, DCs play an important role in patients with rheumatoid arthritis (RA), and the basic mechanism is initiation and maintenance of inflammation by presenting antigens to autoreactive T cell [3] .
T helper cells that produce IL-17 (Th17 cells) has been recognized as a unique subset of effector T cells and implicated as potent effectors of autoimmune disorders, such as RA. Th17 cells played a protective role against infections at mucosal surfaces, whereas regulatory T cells (Tregs) controlled immune responses and inflammation triggered by the resident microflora [4] [5] [6] . Pesce and Samson [7, 8] found that IL-6 receptor could blockade the balance between Tregs and Th17 cells and inhibition of IL-6 function could correct Th17/Treg cell imbalance in patients with RA.
Recently, several studies reported that microRNAs were important regulators of the immune response [9] . A significant increase in miR-146a, miR-155, miR-132 and miR-16 in PBMCs from RA patients compared with healthy and diseased control individuals has been reported, suggesting that miRNAs can be involved in the regulation of RA pathogenesis [10] . miR-363 expression was downregulated in CD4 + T cells of patients with RA [11, 12] ; however, its expression in DCs is still unknown. In this study, we elucidated miR-363 expression and its regulation mechanism in DCs, aiming to further explore the effect of miR-363 expression on Th17/Treg cell balance in patients with RA.
In addition, research has highlighted that integrin av expression by DCs was required for Th17 cell differentiation [13] . DCs expressing integrin av can activate TGF-b, which was essential for the generation Tregs [14] . However, the relationship between miR-363 and integrin av has no reported yet. Taken together, this study mainly studied the effect of DCs from peripheral blood on the differentiation of Th17 through miR-363/ integrin av/TGF-b pathway in patients with RA.
Materials and method
Participants. This study group comprised 30 patients with RA and 20 healthy controls. The characteristics of patients with RA and healthy controls are given in Table 1 . The study was approved by the ethics committee of the affiliated hospital, Hangzhou Normal University.
Peripheral blood samples that obtained from patients and healthy controls were placed in tubes free of pyrogen and endotoxin. The serum samples were collected after centrifugation at 1000 g for 15 min, and stored at À70°C until ready for use.
PBMC purification and culture. Human PBMCs were isolated from peripheral blood of patients with RA and healthy person via density gradient centrifugation using FicollHypaque (Amersham Pharmacia Biotech, Sweden). The cells were counted in a Neubauer chamber, and cell viability was determined using the Trypan Blue (Sigma-Aldrich, St. Louis, MO, USA) exclusion method. Cells were only used when their viability was>98%. The acquired PBMCs were incubated at 37°C in a humidified 5% CO 2 incubator using complete RPMI 1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% foetal bovine serum(Gibco) and penicillin (10.000 U/ml)/streptomycin (10.000 mg/ml) (Gibco).
Cell separation and coculture. Naive CD4 + T cells were sorted by magnetic separation using CD4 +
CD25
+ regulatory T cell selection kit (Stem Cell Technologies, Vancouver, BC, Canada). Purity of more than 95% was routinely achieved. T cells were cultured in X-VIVO 15 medium (Lonza, Verviers, Belgium) supplemented with penicillin (100 U/ml), streptomycin (100 lg/ml), 2-bmercaptoethanol (50 lM) for all experiments except RGD blockade. CD11c + DCs were sorted to more than 95% purity using CD11c microbeads (Miltenyi Biotec, San Diego, CA).
The DCs were derived from PBMCs. Firstly, the PBMCs were obtained from standard buffy-coat preparations from patients with RA by centrifugation over FicollHypaque gradients (Lymphoprep, Norway). Secondly, monocytes were isolated from PBMCs by negative selection using the Human Monocyte Enrichment Kit (EasySep, Canada). Lastly, immature DCs were obtained from isolated monocytes by standard procedures. Briefly, monocytes were cultured in 12-well plates for 7 days with complete RPMI medium containing 2 mM L-glutamine, 10% foetal calf serum and 100 mg/ml streptomycin and ampicillin. At days 3, 0.5 ml of the medium was removed and replaced by freshly made GM-CSF (Leukine; Berlex Laboratories Inc., Richmond, CA)-and IL-4 (R&D Systems, Minneapolis, MN, USA)-containing medium. At day 7, immature DCs (iDC) were recovered, washed and resuspended in RPMI medium for subsequent maturation. Immature DCs were cultured in 6-well plate for 24 h in complete medium only or supplemented with 50 ng/ml TNF-a and 50 ng/ml IL-1b (R&D Systems) to generate mature DC (mDC).
The coculture containing 1*10 5 DCs and 2.5*10 5 naive CD4 + T cells in RPMI 1640 with 0.5 lg/ml anti-CD3 (145-2C11; BD Biosciences), 10% FBS, 2 mM L-glutamine, 100U/ml penicillin, 100 g/ml streptomycin, 50uM b-mercaptoethanol and 20 ng/ml IL-6 and additional cytokines used were recombinant active TGF-b (aTGF-b, R&D Systems, 1 ng/ml,), purified human latent TGF-b (lTGF-b, R&D Systems, 20 ng/ml). For cRGD (cyclic arginine-glycine-aspartic acid tripeptide, a targeting ligand to integrin a(v)b(3) receptor, integrin am inhibitor) blockade experiments, cRGD peptide was added at 2 lg/ ml. Cells were cultured for 4 or 5 days before analysis of Th17 differentiation.
DCs transfection. The miR-363 mimics and miR-NC (negative control of miR-363) were purchased from Transheep (Shanghai, China). DCs transfection with miR-363 mimics and miR-NC was performed using lipofectamine 2000 (Invitrogen Corp. Carlsbad, CA, USA) according to the manufacturer's instructions.
Flow cytometry. For analysis of Th17 cells, PBMCs were suspended in complete culture medium (RPMI-1640 supplemented with 10% foetal calf serum) for 5 h at 37°C in 5% CO 2 . Then the cells were incubated with human APC-anti-CD3 and FITC-anti-CD8a mAbs (eBioscience, San Diego, CA, USA), washed, fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, California, USA). At last, cells were intracellularly stained with PE-anti-IL-17A or its isotype controls (PE-conjugated rat IgG1, eBioscience, USA) for 1 h at room temperature.
For analysis of Tregs, PBMC were surface stained with human FITC-anti-CD4mAb, and APC-anti-CD25mAb, followed by fixation and permeabilization with Cytofix/ Cytoperm and intracellular staining with PE-anti-Foxp3 or PE-IgG2a rat IgG control antibody (eBioscience, USA) according to the manufacturer's instructions. Data were collected on a flow cytometer using Cell Quest software (BD Biosciences, San Jose, CA, USA).The effect of other stimulators on Th17 cell was also analysed. For analysis of CD11c + am + DCs, CD11c + DCs were collected and surface stained with human FITC-antiIntegrin av, followed by fixation and permeabilization with Cytofix/Cytoperm and intracellular staining with PE-IgG1 mouse (IgG control antibody; eBioscience, USA) as described above.
RNA isolation and RT-qPCR. The total RNA were isolated from cells with TRIZOL reagent (SIGMA). Reverse transcription was performed with PrimeScript RT reagent Kit (Takara, Japan) according to the manufacturer's protocol. qRT-PCR was performed with SYBR PrimeScript RT-PCR Kits (Takara, Japan) based on the manufacturer's instructions. The expression of ITGAV, Foxp3 and ROR-ct was calculated with the 2-DDCt method, which was normalized to b-actin mRNA. And the TaqMan microRNA Reverse Transcription Kit and TaqMan Universal Master Mix II with the TaqMan MicroRNA Assay of miRNAs (Applied Biosystems, Foster City, CA, USA) were used for detecting the miR-363 expression. All assays were performed in triplicate. Western blot. After various treatments, cells were collected and lysed in protein lysis buffer. The total protein concentration was determined by Coomassie brilliant blue protein assay. Proteins samples (30 lg) were separated on SDS-12% PAGE and then transferred onto PVDF membranes (Millipore, USA). The blots were incubated with appropriate primary antibody, anti-integrin av antibody from Abcam (ab208012) for overnight at 4°C. Then membranes were washed and incubated with HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Band intensity was quantified by Quantity One software. The protein expression was normalized to b-actin levels.
Determination of cytokines. The peripheral blood serum or cell culture supernatant was collected to quantitatively measure IL-17, IL-6, TGF-ß concentrations using the ELISA kits from Jingmei Co. Ltd (Beijing, China) according to the manufacturer's instructions.
Statistical analysis. The statistical analysis was conducted by SPSS 17.0 software (Chicago, USA). Data were presented as mean AE standard deviation, and statistical analyses were performed using Student's t-test with a significance level of P < 0.05. Correlation analysis was used to estimate the relationship between Th17 or Th17/ Treg ratio and CD11c + av + /CD11c + DCs, and the expression level of ITGAV and miR-363.
Result
Th17 cell amount and the Th17/Treg ratio were increased in patients with RA
We enrolled a total of 30 RA patients consisting of 18 females and 12 males with mean disease duration of 8.6 AE 6.4 years and mean age of 48.5 AE 9.4 years. The 20 healthy controls included 11 females and nine males, with a mean age of 42.3 AE 10.6 years. The level of erythrocyte sedimentation rate (ESR) and C-reactive protein (CPR) was both higher in patients with RA than those in healthy controls. As Table 1 showed the RF positive/ negative ratio is 16 of 14 and the mean DAS28 is 5.9 AE 1. Fig. 1B and D) . Therefore, the Th17/Treg ratio was significantly increased in patients with RA (Fig. 1E) .
MiR-363 expression was decreased in patients with RA, and ITGAV was inversed The Foxp3 is a specific marker of Treg cells, and ROR-ct is a key transcription factor of Th17 cells. In this study, the relative mRNA expression of Foxp3 and ROR-ct in PBMCs was detected by RT-PCR. As Figs. 2A and B showed, the expression of Foxp3 was significantly declined, while ROR-ct was rising in patients with RA. Also, the increased ROR-ct expression was consistent with the cell proportion of Th17 cells and Treg cells in PBMCs of patients with RA.
Li et al. [11] had reported that, miR-363 expression was downregulated in CD4 + T cells of patients with RA. Integrin av is an important physiological regulator of TGF-b activation, and deletion of Integrin av or disruption of the av-binding site in TGF-b causes failure of effective TGF-b signalling in vivo [15] . Therefore, we analysed the relative mRNA expression of miR-363 and ITGAV (coding Integrin av) in PBMCs by RT-PCR. As Fig. 2C showed, the miR-363 expression of PBMCs was significantly downregulated in patients with RA, and the result was in accord with the previously reported. However, the ITGAV expression of PBMCs was significantly upregulated in patients with RA (Fig. 2D) .
Serum IL-17 and IL-6 increased accompany with TGF-b in patients with RA IL-17, TGF-b and IL-6 are Th17-related cytokines, which have pro-inflammatory effects, and IL-17 is the main effect factor of Th17 cells. In this study, IL-17, TGF-b and IL-6 levels in peripheral blood serum were evaluated by ELISA. In addition, the TGF-b is secreted by cells as an inactive precursor that must be activated to exert biological effects. So the TGF-b levels in serum were detected after the serum with acidification treatment to induce immune response. As shown in Fig. 3 , the IL-17, IL-6 and TGF-b levels were obviously upregulated in patients with RA, suggesting that the pro-inflammatory effects of IL-17, IL-6 and TGF-b on RA disease development. + Treg cells from na€ ıve T cells [16] . Naive T cells can differentiate into Treg and Th17 cells expressing Foxp3 and IL-17, respectively. Moreover, there was no correlation between integrin am expression and the Th17/Treg ratio in separated Th0 cells (Naive CD4 + T cells, data were not shown).
Integrin am and miR-363 were negatively correlated in cultivated DCs
The expression of integrin am and miR-363 and relationship between them were detected and discussed, respectively. As shown in Fig. 5A , there were obvious decreased miR-363 level and increased ITGAV level in cultivated DCs of patients with RA. And the Western blot results showed the integrin am protein expression of patients with RA were increased as well (Fig. 5C ). In addition, we found that the miR-363 and ITGAV expression had an inverse relationship (Fig. 5B , R 2 = 0.2171, P = 0.0095).
Integrin av promote Th17 cells differentiation by activating latent TGF-b
The separated naive CD4 + T cells and CD11C + DC cells by immunomagnetic bead (IMB) were cocultured to detect Th17 cell differentiation after cultured 4-5 days. DCs cultured with T cells alone did not generate significant numbers of Th17 cells, whereas addition of active TGF-b (aTGF-b) stimulated generation of Th17 cells. As Fig. 6A showed, no significant changes were found in the influence of CD11C + DC cells and cRGD on Th17 cell differentiation in the presence of active TGF-b (aTGF-b); however, the Th17 cell number was significantly reduced when latent TGF-b (ITGF-b) replaced aTGF-b. The change of IL-17 and ROR-ct levels was almost consistent with Th17 cell number. As shown in 
miR-363 inhibit integrin av expression and Th17 cell differentiation
The miR-363 mimics and miR-NC were transfected into DCs, which were cocultured with T cells as previously culture conditions. In the presence of aTGF-b, miR-363 mimic did not affect the Th17 cells number, IL-17 level and ROR-ct mRNA expression, but in the presence of ITGF-b, they were all significantly declined in miR-363 transfection group (Fig. 7A, B and C) . In addition, we also detected the integrin am protein levels by Western blot. As the Fig. 7D showed, integrin am expression of miR-363 mimic transfection DCs was reduced in the presence of active and inactive TGF-b.
Discussion
Rheumatoid arthritis (RA) is an autoimmune disease, which is characterized by chronic, progressive and invasive arthritis [17] . The Th17 cells and Treg cells are both T lymphocyte subsets, while they have opposite effects on autoimmunity and inflammation [18] . The imbalance of Th17/Treg cell populations has been reported to involve in the regulation of RA pathogenesis [19] . Lina and colleagues reported that Th17/Treg balance was impaired in the peripheral blood of patients with RA [20] . Consistent with these reporters, our study demonstrated increased ratio of Th17 cells to Treg cells in the PBMCs of patients with RA ( Fig. 1) .
In human, Th17 cells can be induced by IL-6, which is abundant in the inflamed joint in patients with active RA and is directly involved in the destruction of cartilage and bone [10, 21] . Production of IL-17 is the characteristic of Th17 cells [22] . The differentiation factors (TGF-b) and the transcription factors (ROR-ct) have been identified to involve in the development of Th17 cells [23] . Integrin av and TGF-b were required for differentiation of Th17 cells [13, 24] . Consistent with these reporters, we found that IL-6, IL-17 and TGF-b levels were obviously upregulated in RA patients' peripheral blood serum (Fig. 3) , and ROR-ct and Integrin av expressions were also significantly upregulated in PBMCs of patients with RA (Fig. 2) . Our study + T cell were analysed by flow cytometry. Th17 cell count had no obvious difference after adding cRGD into culture system that containing aTGF-b, but it had significantly reduced in culture system that containing ITGF-b after adding cRGD. In addition, the proportion of Th17 cell to CD4 + T cell in the group that containing aTGF-b and cRGD was also higher than that containing ITGF-b and cRGD, which suggesting that aTGF-b stimulated generation of Th17 cells (B).The IL-17 levels change was almost consistent with Th17 cell number. (C). The ROR-ct mRNA expression was significantly decreased after adding cRGD into culture system that containing ITGF-b, but no obvious difference when that containing aTGF-b. *P < 0.05, **P < 0.01.
implied that development of RA is associated with peripheral Th17/Treg imbalance and characterized by a pro-inflammatory cytokine microenvironment, which supports continuing generation of Th17 cells.
DCs are important for mediating immune responses in the pathogenesis of RA, which is accompanied by the impairment of many DC functions [25] . CD11c + DCs are major players in early immune responses to many viruses, and function in vivo as potent antigen-presenting cells (APCs) that play crucial roles in the enhancement and regulation of cell mediated immune responses. Kvale and colleagues [26] reported that CD11c + DCs were activated by human cytomegalovirus and retained efficient T cellstimulatory capability upon infection. We observed an obvious increase in the CD11C + am + /CD11C + ratio in blood and cultured DCs of patients with RA, and the CD11C + am + /CD11C + ratio was positively correlation with Th17/Treg ratio, suggesting CD11C + am + DCs were advantageous to the Th17 cell differentiation.
It has reported that miR-363 expression was downregulated in CD4 + T cells of patients with RA [11, 12] , and involved in the development of variety of cancer invasion, metastasis and tumorigenesis [27] [28] [29] . In this study, miR-363 expression was reduced in PBMCs and DCs of patients with RA compared to that of the healthy control, which were consistent with previous work. Moreover, our study indicated that there was a strong negative correlation between miR-363 and ITGAV expression, which can encode integrin am. It has reported that integrin am expression from DCs was required for Th17 cell differentiation via activation of latent TGF-b [13] , and Duperret [15] has reported that integrin av was an important physiological regulator of TGF-b activation, and deletion of integrin av or disruption of the av-binding site in TGF-b causes failure of effective TGF-b signalling in vivo. Consistently, the ratio of CD11c + am + /CD11c + was positively correlated with the ratio of Th17/Treg cells in DCs from patients with RA. Therefore, miR-363/integrin av/TGF-b axis plays an important role in Th17 cell differentiation In summary, our data demonstrate that DCs derived from peripheral blood of patients with RA can induce Th17 cell differentiation. The possible mechanism is that the miR-363 expression which is negatively related to the integrin av expression is low in DCs of patients with RA, and upregulated integrin av could induce TGF-b activation to promote Th17 cell differentiation. cRGD, known as integrin av inhibitor, has same function to miR-363 mimics that could inhibit the integrin av expression and Th17 cell differentiation. Our data further suggest that disruption of this DC/miR-363/integrin av/TGF-b dialogue is a potential therapeutic option in Th17-mediated diseases. 
